Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like <b>Mike Hooven</b>, Founder Of AtriCure And Enable Injections, Joins Genetesis Board Of Directors October 10, 2017 NW Bio Closes 3-Year Convertible Debt Exchange And Financing, And Completes Payoff Of Last $5 Million Of 2014 Bonds June 21, 2017 Teva's CGRP Migraine Med Hits a Stumbling Block February 8, 2018
<b>Mike Hooven</b>, Founder Of AtriCure And Enable Injections, Joins Genetesis Board Of Directors October 10, 2017
NW Bio Closes 3-Year Convertible Debt Exchange And Financing, And Completes Payoff Of Last $5 Million Of 2014 Bonds June 21, 2017
